Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

Dan Liu; Zefeng Xu; Peihong Zhang; Tiejun Qin; Xiujuan Sun; Shiqiang Qu; Lijuan Pan; Jiao Ma; Wenyu Cai; Jinqin Liu; Huijun Wang; Qi Sun; Zhongxun Shi; Huijun Huang; Gang Huang; Robert Peter Gale; Bing Li; Raajit K Rampal; Zhijian Xiao

doi:10.3324/haematol.2021.280080

Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

Haematologica. 2022 Apr 1;107(4):991-995. doi: 10.3324/haematol.2021.280080.

Authors

Dan Liu¹, Zefeng Xu¹, Peihong Zhang², Tiejun Qin¹, Xiujuan Sun³, Shiqiang Qu¹, Lijuan Pan¹, Jiao Ma², Wenyu Cai², Jinqin Liu³, Huijun Wang², Qi Sun², Zhongxun Shi¹, Huijun Huang¹, Gang Huang⁴, Robert Peter Gale⁵, Bing Li⁶, Raajit K Rampal⁷, Zhijian Xiao⁸

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin.
² State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin.
³ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin.
⁴ Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
⁵ Haematology Section, Division of Experimental Medicine, Department of Medicine, Imperial College London, London.
⁶ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin. libing@ihcams.ac.cn.
⁷ Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. rampalr@mskcc.org.
⁸ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin. zjxiao@ihcams.ac.cn.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Hydroxyurea* / therapeutic use
Interferon-alpha
Polycythemia Vera* / diagnosis
Polycythemia Vera* / drug therapy
Retrospective Studies

Substances

Interferon-alpha
Hydroxyurea

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States